Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Current Deferred Revenue: 2016-2024

Historic Current Deferred Revenue for Tg Therapeutics (TGTX) over the last 9 years, with Dec 2024 value amounting to $11.4 million.

  • Tg Therapeutics' Current Deferred Revenue rose 190.32% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.4 million, marking a year-over-year increase of 190.32%. This contributed to the annual value of $11.4 million for FY2024, which is 7409.21% up from last year.
  • According to the latest figures from FY2024, Tg Therapeutics' Current Deferred Revenue is $11.4 million, which was up 7,409.21% from $152,000 recorded in FY2023.
  • Tg Therapeutics' Current Deferred Revenue's 5-year high stood at $11.4 million during FY2024, with a 5-year trough of $152,000 in FY2023.
  • Moreover, its 3-year median value for Current Deferred Revenue was $500,000 (2022), whereas its average is $4.0 million.
  • Per our database at Business Quant, Tg Therapeutics' Current Deferred Revenue slumped by 69.60% in 2023 and then spiked by 7,409.21% in 2024.
  • Over the past 5 years, Tg Therapeutics' Current Deferred Revenue (Yearly) stood at $800,000 in 2020, then dropped by 25.00% to $600,000 in 2021, then fell by 16.67% to $500,000 in 2022, then tumbled by 69.60% to $152,000 in 2023, then soared by 7,409.21% to $11.4 million in 2024.